AstraZeneca (AZN)
(Delayed Data from NSDQ)
$79.33 USD
-2.48 (-3.03%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $79.34 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.33 USD
-2.48 (-3.03%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $79.34 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Lilly/AstraZeneca Expand Alzheimer Disease Collaboration
by Zacks Equity Research
Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814
Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs
by Arpita Dutt
Drug pricing is back in focus with president-elect Trump making it clear that he does not like price increases.
AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting
by Zacks Equity Research
AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.
Top Research Reports for Cisco, Merck & MasterCard
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including MasterCard (MA), Merck (MRK) and Cisco (CSCO).
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda
by Arpita Dutt
This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.
Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?
by Eric Dutram
In this edition of the Dutram Report, Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments who specializes in the world of immunotherapy. This approach is revolutionizing the cancer treatment market, and we get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look.
Argument for Interest Rate Hike "Quite Strong"
by Mark Vickery
Fed Vice Chair Stanley Fischer said he is optimistic a rate hike would be manageable abroad, and that a stronger U.S. economy should help other countries.
Is Brexit a Buying Opportunity?
by Tracey Ryniec
Value investors should keep an eye on what is going on in Great Britain right now.
Market News Over Summer Vacation: PFE, AZN, TSLA, LZB
by Mark Vickery
You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.
Low PE Stocks For This Market
by Brian Bolan
A look at four stocks with low PE's and earnings estimate revisions that are among the best over the last four weeks.
Pharma Stock Outlook: Let's Make a Deal
by Arpita Dutt
M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.
Pharma Stock Outlook: Let's Make a Deal
by Arpita Dutt
M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.